FR - Tratamiento intralesional del cáncer cutáneo no melanoma con 5-fluorouracilo

Gil-Lianes, Javier; Morgado‐Carrasco, Daniel

doi:10.1016/j.ad.2021.07.029

Cited by 3 publications

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A phase 1 clinical trial (NCT03370406) is recruiting patients with cSCC in the lower extremities for treatment with il5-FU and topical imiquimod [ 55 ]. il5-FU is a well-tolerated procedure, with adverse events being mostly mild and local (pain and injection site reactions) and rarely systemic (including headache, dizziness, and nausea) [ 51 , 53 , 54 , 56 , 57 ]. Follow-up time has been inconsistent among the case reports and series, most of them less than 1 year, if stated [ 7 , 51 ].…”

Section: Classic Treatmentsmentioning

confidence: 99%

Intralesional Treatments for Invasive Cutaneous Squamous Cell Carcinoma

Baeza-Hernández,

Cañueto

2023

Cancers

View full text Add to dashboard Cite

Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans and has the potential to progress locally, metastasize, and cause death in a subset of patients. cSCC is especially common in the elderly, and it will probably represent a major health concern in the near future. Surgery is the standard treatment for cSCC, but intralesional therapies can sometimes be considered for certain patients and under certain circumstances. The choice of intralesional treatment depends on the patient′s characteristics and the clinician′s previous experience and expertise. Here we are reviewing intralesional treatments for cSCC and keratoacanthoma (KA). We have started with some classic drugs, such as methotrexate and 5-fluorouracil, bleomycin, interferon, and cryosurgery, but also comment on electrochemotherapy. Finally, we have focused on novel therapies, some of which are under development, and future perspectives, including intralesional immunotherapy and oncolytic viruses.

show abstract